"Analysis.group","Analysis.number","Analysis.name","Subgroup","Applicability","Study","Study.year","GIV.Mean","GIV.SE","Experimental.mean","Experimental.SD","Experimental.cases","Experimental.N","Control.mean","Control.SD","Control.cases","Control.N","O.E","Variance","Weight","Mean","CI.start","CI.end","Footnotes","Bias.arising.from.the.randomization.process.judgement","Bias.arising.from.the.randomization.process.support","Bias.due.to.deviations.from.intended.interventions.judgement","Bias.due.to.deviations.from.intended.interventions.support","Bias.due.to.missing.outcome.data.judgement","Bias.due.to.missing.outcome.data.support","Bias.in.measurement.of.the.outcome.judgement","Bias.in.measurement.of.the.outcome.support","Bias.in.selection.of.the.reported.result.judgement","Bias.in.selection.of.the.reported.result.support","Overall.bias.judgement","Overall.bias.support","review.url","review.doi","analysis_key","dataset_name","mismatch_type","direction_match","or_sig","rd_sig","log_or","rd","log_or_ci_lb","log_or_ci_ub","rd_ci_lb","rd_ci_ub","sparse_events","double_zero"
1,1,"All-cause mortality at day 28","","SUBGROUP_AND_OVERALL","EPIC-HR 2021",2021,0,0,0,0,0,1109,0,0,12,1115,0,0,100,0.040216,0.002384,0.678408,"Time point (28 days), participants (WHO 2 to 3, unvaccinated, high risk); intervention (nirmatrelvir/ritonavir); comparator (placebo)","Low risk","<p>Centralized web-based randomization. There are no baseline differences that would suggest a problem with randomization.</p>","Some concerns","<p>Both participants and those delivering the intervention were not aware of intervention received. The analysis was not appropriate (a per-protocol analysis was used).</p>","Low risk","<p>Data for this outcome were reported for all participants of the mITT2 population.</p>","Low risk","<p>Measurement of the outcome was appropriate. Outcome assessors were not aware of the intervention received.</p>","Low risk","<p>The protocol was prospectively registered and the outcome was reported as registered.</p>","Some concerns","<p>Due to per-protocol analysis (mITT2). </p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015395.pub3/full","10.1002/14651858.CD015395.pub3","1::overall","CD015395_pub3_data","significance_only",TRUE,FALSE,TRUE,-1.54030872055674,-0.0109216825837332,-4.14206476745135,1.06144732633787,-0.0169376121276952,-0.00490575303977115,FALSE,FALSE
2,1,"All-cause mortality at day 28","","SUBGROUP_AND_OVERALL","Liu 2023",2023,0,0,0,0,5,132,0,0,8,132,0,0,100,0.625,0.209926,1.860772,"Time point (28 days), participants (WHO 2 to 4, high risk, 25% vaccinated); nirmatrelvir/ritonavir vs SoC","Low risk","<p>Centralized web-based randomization. There are no baseline differences that would suggest a problem with randomization.</p>","Low risk","<p>Participants were aware of intervention received; those delivering the intervention were not. The analysis was appropriate (all participants were analyzed as randomized).</p>","Low risk","<p>Data for this outcome were reported for all participants of the study population.</p>","Low risk","<p>Open-label trial; unclear whether the outcome assessor was blinded. However, outcome assessment does not involve judgement.</p>","Low risk","<p>The protocol was prospectively registered and the outcome was reported as registered.</p>","Low risk","<p>No concerns.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015395.pub3/full","10.1002/14651858.CD015395.pub3","1::overall","CD015395_pub3_data","significance_only",TRUE,FALSE,TRUE,-1.54030872055674,-0.0109216825837332,-4.14206476745135,1.06144732633787,-0.0169376121276952,-0.00490575303977115,FALSE,FALSE
